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Background: Survival and prosthetic complications of patients receiving the Han-
cock II second-generation bioprosthesis (Medtronic, Inc, Minneapolis, Minn) in the
aortic, mitral, mitral-aortic, and tricuspid positions were analyzed at 15 years’
follow-up.
Methods: Between May 1983 and December 1993, 212 patients (104 men and 108
women; mean age, 63  9 years; age range, 29-81 years) received 66 aortic, 114
mitral, 26 mitral-aortic, and 6 tricuspid Hancock II valves. Thirty-one percent of
patients had previous valve operations, 15% had concomitant cardiac procedures,
and 87% were in New York Heart Association class III or IV. Follow-up included
1704 patient-years and was 98% complete, with a median of 9 patient-years (range,
0.013-17.4 years). Forty-six patients were at risk at 14 to 15 years, and 30 were at
risk after 15 years.
Results: One hundred twenty-two (57%) of 212 patients died, 20 of them periop-
eratively. Fifteen-year actuarial Kaplan-Meier survival was 35.2%  3.8%, and
freedom from valve-related mortality was 84%  3.5%, with no difference on the
basis of position or age (65 or 65 years). Percentages for freedom from
thromboembolism, anticoagulant-related hemorrhage, endocarditis, and paravalvu-
lar leak were, respectively, 78.2%  4%, 83.5%  3.6%, 95.7%  2%, and 97.3%
 1.4%, with no significant difference between the aortic and mitral positions.
Freedom from structural valve deterioration was 71.8%  5.6%: 88.9%  6.2% in
the aortic position versus 59.5%  3.9% in the mitral position (P  .01) and 64.3%
 3% in the mitral-aortic position. In patients younger than 65 years, actual freedom
from structural valve deterioration was less than that seen in older patients (84.5%
 3.5% vs 95% 3.0%) and was better in the aortic versus the mitral position (92%
 4.5% vs 82%  4.2%).
Conclusion: The Hancock II porcine valve showed excellent 15-year durability. We
recommend its use in patients 65 years of age, as well as in younger patients
undergoing aortic replacement.
Porcine bioprostheses have been used since the late 1960s.1 Over time,prosthetic valve–related complications caused by structural2 and non-structural valve dysfunction forced the replacement of many earlyprosthetic valves within 10 years from implantation.3Tissue processing and valve engineering were modified to enhancelong-term performance. In 1982, the second-generation Hancock
valve bioprosthesis (Hancock II; Medtronic, Inc, Minneapolis, Minn) was commer-
cialized. It is a porcine bioprosthesis fixed in glutaraldehyde (0.625%) at low
pressure to preserve the natural collagen crimping, treated with calcium-retarding
agent (T6 sodium dodecyl sulfate), and mounted on a low-profile Delrin stent
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(DuPont, Wilmington, Del).4 Excellent durability has been
proved in intermediate follow-up, and therefore an im-
proved long-term performance was expected when com-
pared with that of the Hancock Standard valve bioprosthe-
sis.5-7
This study evaluates the 15-year clinical performance
and complication rate of patients who underwent aortic,
mitral, double-valve, or tricuspid replacement with Hancock
II porcine bioprostheses and updates the excellent interme-
diate follow-up results by Bortolotti and colleagues in the
American Journal of Cardiology in 1994.5
Patients and Methods
Between May 1983 and December 1993, 212 patients (104 men
and 108 women; mean age, 63  9 years; age range, 29-81 years)
underwent 238 heart valve replacements with Hancock II porcine
bioprostheses. The median age was 63.5 years, and 121 patients
were younger than 65 years (26 aortic, 73 mitral, 17 mitral-aortic,
and 5 tricuspid replacements).
Preoperative data are detailed in Table 1. Sixty-six procedures
involved isolated aortic, 99 isolated mitral, and 26 combined
mitral-aortic Hancock II placement. An additional 15 mitral Han-
cock II and 6 tricuspid bioprostheses, with concomitant different
aortic prostheses or repairs, were analyzed as single Hancock II
procedures.
Eighty-seven percent (184/212) of patients were in New York
Heart Association (NYHA) functional class III or IV.
Aortic prosthesis size was 23 mm in 38.5% of patients, 25 mm
in 48.5% of patients, and 27 mm in 13% of patients. The indexed
effective orifice area was greater than 1 in all but 9 cases. Mitral
prosthesis size was 27 mm in 3.7% of patients, 29 mm in 44.8% of
patients, 31 mm in 42.7% of patients, and 33 mm in 8.8% of
patients. The indexed effective orifice area was greater than 1.7 in
all but 6 cases.
Sixty-six (31%) patients had previously received a different
prosthesis: 8 (12.2%) underwent aortic valve replacement, 49
(74.2%) underwent mitral replacement, 5 (7.6%) underwent dou-
ble-valve replacement, and 4 (6%) underwent tricuspid valve re-
placement.
Concomitant procedures included coronary revasculariza-
tion (18/212 [8.5%]) and aortic annular enlargement or aorto-
plasty (10/212 [5%]). Explanted bioprostheses underwent mi-
croradiographic, histologic, and ultrastructural examination, as
previously reported.2 Details of pathology will be reported
elsewhere.
Surgical Technique
Median sternotomy, cardiopulmonary bypass, moderate hypother-
mia, and aortic crossclamping were used in all patients. Cardiople-
gic arrest was achieved with antegrade cold crystalloid infusion
repeated at 20-minute intervals, with additional topical cooling.
Valves were implanted through a transaortic approach or
through a paraseptal left atrial incision by using multiple inter-
rupted sutures of 2-0 Ti-Cron (American Cyanamid Co, Danbury,
Conn) reinforced by Teflon pledgets. Posterior mitral chordae were
occasionally preserved.
Patients with sinus rhythm received oral anticoagulant therapy
for 3 postoperative months to maintain a prothrombin time of less
than 30% of the normal value. Patients with chronic atrial fibril-
lation, left atrial and left ventricular dilatation, double-valve re-
placement, or previous thrombotic episodes were anticoagulated
indefinitely. Aspirin was not prescribed.
Patient Follow-up
Information was obtained annually by means of direct visits,
questionnaires, or telephone interviews. Prospective follow-up was
closed at a common date in July 2001. Cumulative follow-up time
was 1704 patient-years and was 98% complete. Median follow-up
time was 9 years (range, 0.013-17.4 years), and mean follow-up
time was 8.8 years. We limited our analysis to 15 years, with 46
patients at risk between 14 and 15 years and 30 patients at risk
thereafter.
TABLE 1. Preoperative and operative data
Sex All
(104 M,
108 F)
Aortic:
27% F,
73% M
Mitral:
62% F,
38% M
Double:
50% F,
50% M
Tricuspid:
67% F,
33% M
Mean age (y) All
(212 patients),
63  9
Aortic
(66 patients),
67  8.2
Mitral
(114 patients),
61.2  8.7
Mitral-aortic
(26 patients),
61.4  5.8
Tricuspid
(6 patients),
54.8  8.9
Previous valve
procedures (n)
All,
66 patients
Aortic,
8 patients
Mitral,
49 patients
Mitral-aortic,
5 patients
Tricuspid,
4 patients
NYHA class III-IV (%) 87 75 87 90 90
Rhythm (%):
Sinusal 35 83 13 20 17
Atrial fibrillation 62 11 86 80 67
Pacemaker 3 6 1 0 16
Concomitant procedures (n)
CABG 18 15 2 1 0
Aortoplasty/replacement 5 4 0 1 0
Annulus enlargement 5 5 0 0 0
CABG, Coronary artery bypass grafting.
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Statistical Analysis
Postoperative complications and prostheses-related events (struc-
tural valve deterioration [SVD], thromboembolism, anticoagulant-
related hemorrhage, endocarditis, paravalvular leak, reoperations,
and valve-related morbidity) were defined as previously pub-
lished.8
Estimates of postoperative complications and prostheses-re-
lated events were calculated by means of the Kaplan-Meier
method and expressed as percentage  SE or percentage  95%
confidence interval (CI). Statistical comparison of survival curves
was made with the log-rank test. Actual versus actuarial freedom
from SVD was calculated by using the method of Grunkemeier
and coworkers,9 and the SE of the actual estimates was calculated
with the method of Gaynor and associates.10 Actual calculations
were made on a prosthetic basis (5 aortic and 20 mitral SVD
events).
Results
Postoperative and follow-up data are summarized in Table
2.
Perioperative (30-Day) Mortality
Twenty patients died, 9 of them at reoperation. Overall
mortality was 9.4% (95% CI, 5.8%-14.2%): 4.5% (3/66;
95% CI, 9.4%-12.7%) in the aortic, 11.4% (13/114; 95% CI,
6.2%-18.7%) in the mitral, and 15.3% (4/26; 95% CI, 4.3%-
35%) in the mitral-aortic position. All patients were in
NYHA class III or IV. Mean patient age was 76 4.5 years
in the aortic, 66  8 years in the mitral, and 63  3.7 years
in the mitral-aortic position. One patient undergoing aortic
replacement had a concomitant Manouguian procedure,11
and 1 patient undergoing mitral replacement had an aorta-
coronary bypass graft. Fifteen deaths were cardiac related,
and 5 were valve related.
Late Mortality
We observed 102 late deaths (102/192 [53.1%] patients),
with an overall 15-year Kaplan-Meier survival of 35.2% 
3.8% (95% CI, 27.7%-42.7%; Figure 1). Thirty-five deaths
occurred in patients undergoing aortic valve replacement
(28%  8% 15-year Kaplan-Meier survival), 53 in patients
undergoing mitral valve replacement (37%  5.3% 15-year
Kaplan-Meier survival), 12 in patients undergoing mitral-
aortic valve replacement (31%  10% 15-year Kaplan-
Meier survival), and 2 in patients undergoing tricuspid
valve replacement (62%  21% 15-year Kaplan-Meier sur-
vival).
These survivals were not significantly different. Fifteen-
year Kaplan-Meier survival of patients younger than 65
years was 44.5% 5% versus 19% 6% for older patients
(P  .0034).
Forty-five (44%) late deaths were cardiac related, 17
(16.8%) were valve related, and 40 (39.2%) were noncar-
diac and nonvalve related.
Valve-Related Death
Among the 5 perioperative (early) deaths and 17 late valve-
related deaths, 6 (17%; 1 early and 5 late deaths) occurred
in patients undergoing aortic valve replacement (1 prosthet-
ic-valve thrombosis, 1 sudden death, 1 SVD, 1 endocarditis,
1 cerebral event, and 1 peripheral hemorrhagic event), 14
(27%; 3 early and 11 late deaths) occurred in patients
undergoing mitral valve replacement (1 sudden death, 2
SVD, 2 valve endocarditis, 1 prosthetic-annulus dehiscence,
1 prosthetic valve thrombosis, 2 cerebral events, 1 periph-
eral hemorrhagic event, and 4 thromboembolisms), and the
last 2 deaths (17%; 1 early and 1 late death) occurred in
patients undergoing mitral-aortic replacement (both throm-
boembolisms).
Fifteen-year Kaplan-Meier freedom from valve-related
mortality was 84%  3.5% (95% CI, 75.5%-89.6%; Figure
2); it was 83%  8% for the aortic position, 79%  5.2%
for the mitral position, and 90%  6.5% for the mitral-
aortic position (P  .72).
Ten valve-related deaths occurred in patients younger
than 65 years of age, and 12 occurred in older patients:
15-year freedom from valve-related death was 87% 3.5%
in younger and 73%  10% in older patients (P  .48).
Thromboembolism
Thirty-two bioprosthesis-related major thromboembolic
events occurred in 29 patients (9 in patients undergoing
aortic, 16 in patients undergoing mitral, and 7 in patients
undergoing mitral-aortic replacement) with 2 early and 4
late deaths (4 in patients undergoing mitral and 2 in patients
undergoing mitral-aortic valve replacement). Linearized
rates were 1.8% per patient-year in aortic, 1.7% in mitral,
and 2.7% in double prostheses.
Three prosthetic valve thromboses were observed. One
patient undergoing mitral valve replacement underwent suc-
cessful reoperation of bioprosthetic and left atrium toilette 2
TABLE 2. Postoperative and late data
Early Late
Deaths 20 (9.4%) 102 (53.1%)
Cardiac-related death 15 (75%) 45 (44.5%)
Valve-related death: 5 (25%) 17 (16.8%)
SVD 3
Cerebral hemorrhage 3
Periferic hemorrhage 1 1
Thrombosis 1 1
Thromboembolism 2 4
Prosthetic-annulus dehiscence 1
Endocarditis 3
Sudden 1 1
Anticoagulation 85.28%
NYHA class I-II 74.42%
Rhythm SR 27% AF 63% PM 10%
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years after the prosthesis was implanted. The second patient
undergoing mitral valve replacement experienced thrombo-
sis 7 years after the operation, was medically treated, and
died. The last patient had an aortic thrombosis 5 days after
the operation and died. Kaplan-Meier freedom from first
thromboembolic occurrence was 78.2%  4% at 15 years,
without a statistical difference between the aortic position
versus the mitral position or versus the mitral-aortic position
(P  .59).
Hemorrhagic Events
Anticoagulation-related major hemorrhages occurred in 23
patients (6 patients undergoing aortic, 10 patients undergo-
ing mitral, and 7 patients undergoing mitral-aortic replace-
ment). Linearized rates were 1.1% per patient-year in aortic,
1.1% in mitral, and 3.7% in double prostheses.
Fatal hemorrhages were cerebral in 3 patients (1 under-
going aortic and 2 undergoing mitral valve replacement)
and peripheral in 2 patients (1 undergoing aortic and 1
undergoing mitral valve replacement). Kaplan-Meier free-
dom from first occurrence of anticoagulant-related hemor-
rhage was 83.5%  3.6% at 15 years, with significantly
lower freedom (67.3% 12%) in double-valve replacement
(P  .01).
Endocarditis
Five patients had endocarditis (1 undergoing aortic and 4
undergoing mitral valve replacement), and 3 of them (1
undergoing aortic and 2 undergoing mitral valve replace-
ment) died at follow-up. Linearized rates were 0.20% per
patient-year in aortic and 0.44% in mitral prostheses.
Among the patients undergoing mitral valve replace-
ment, 2 underwent prosthetic valve replacement. Kaplan-
Meier freedom from prosthetic valve endocarditis was
95.7%  2% at 15 years, without a significant difference
among positions.
Paravalvular Leak
Paravalvular leak occurred in 4 patients. We reoperated on
1 patient who had mitral leak 8.6 years after implantation
and 2 patients with a double-valve leak 4 and 16 months,
respectively, after implantation, both involving only the
mitral valve (1 replaced and 1 sutured). The last patient,
who had an aortic leak after 4 months, was considered, on
Figure 1. Fifteen-year Kaplan-Meier survival. C.L., Confidence limit.
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the basis of 2-dimensional echocardiography, to have a
hemodynamically insignificant leak and was medically
treated. Linearized rates were 0.19% per patient-year in
aortic, 0.11% in mitral, and 1.1% in double prostheses.
Kaplan-Meier freedom from paravalvular leak was
97.3%  1.4% at 15 years, with a significantly lower
freedom (90.4%  6.4%) among the double-valve recipi-
ents (P  .01).
Structural Valve Deterioration
SVD occurred in 22 patients (mean age, 56  9 years): 2
receiving aortic, 16 patients receiving mitral, and 4 patients
receiving mitral-aortic valve replacements. Among the lat-
ter, both valves were affected in 3 patients, and the lone
mitral valve was affected in 1 patient. Seventeen patients
(12 undergoing mitral, 1 undergoing aortic, and 4 undergo-
ing double-valve replacement) with a mean age of 54  9
years underwent reoperation either because of stenosis, in-
competence, or both (20 bioprostheses were explanted).
Overall freedom. Fifteen-year actuarial (Kaplan-Meier)
freedom from SVD was 71.8%  5.6% (95% CI, 58.9%-
81.2%; Figure 3). Actual SVD freedom was 88%  2.5%.
Freedom by position. Fifteen-year actuarial (Kaplan-
Meier) freedom from SVD was 88.9%  6.2% (95% CI,
62.4%-97.1%) in the aortic position, 59.5%  3.9% (95%
CI, 39.8%-74.6%) in the mitral position, and 64.3% 3.0%
(95% CI, 29.8%-85.1%) in double valves (Figure 4). The
difference between the aortic and mitral position was sig-
nificant (P .01). Given 5 aortic and 20 mitral SVD events,
the actual estimate was 92.4%  3.3% in the aortic position
and 85.3%  3.2% in the mitral position.
Freedom by age. Fifteen-year actuarial (Kaplan-Meier)
freedom from SVD was 69% 7% in patients younger than
65 years of age and 83%  8% in older patients.
Fifteen-year actual SVD freedom was 84.5%  3.5% in
patients younger than 65 years and 95%  3.0% in older
patients (Figure 5).
Freedom by age and position. Fifteen-year actual SVD
freedom in patients younger than 65 years was 82% 4.2%
in the mitral position and 92% 4.5% in the aortic position
(P  .0002). In older patients freedom was 91.8%  4.6%
and 93.2%  4.8, respectively. Concerning the isolated
aortic position, both SVD events occurred in patients
younger than 65 years (50 and 56 years, respectively).
Interval to replacement. The interval from implantation
to replacement was 9.7  3.8 years (1.7-16 years). It was
8.5  2.8 years in the aortic position and 9.5  3.7 years in
the mitral position.
Reoperations
Thirty-one patients underwent reoperation: 3 patients un-
dergoing double-valve replacement underwent reoperation
on a failing pericardial tissue valve (2 patients) and a failing
Liotta bioprosthesis (1 patient). One thrombosed Hancock II
mitral prosthesis was preserved after thrombus removal.
Twenty-seven patients had replacement of 29 Hancock II
bioprostheses at a mean operative age of 56.9 9.8 years (1
in the aortic, 20 in the mitral, and 6 in the mitral-aortic
Figure 2. Kaplan-Meier 15-year freedom from valve-related mortality. C.L., Confidence limit.
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positions). The linearized rate was 2.1% per patient-year in
the mitral position, 0.4% in the aortic position, and 3.0% in
the mitral-aortic position. The overall reoperation freedom
(Figure 5) was 69.8%  5.4% at 15 years (95% CI, 57.7%-
79%). Causes of reoperation are reported in Table 3. In 2
patients reoperated on elsewhere, the cause of reoperation
was unknown.
Significantly lower freedom from reoperation was ob-
served in the mitral position (53.4%  9%) versus in the
aortic position (94.4%  5.4%, P  .0038). The actual
freedom of Hancock II reoperation was 81%  3.7% at 15
years in patients younger than 65 years of age and 89.6 
3.8% in older patients.
Valve-Related Complications
There were 86 valve-related complications, including hem-
orrhage, embolism, endocarditis, paravalvular leak, throm-
bosis, and SVD. There were 71 first occurrences and 15
recurrent episodes.
Freedom from all valve-related complications was 40.5%
 4.5% at 15 years. According to prosthetic positions and
operative age, freedom from all valve-related complications
was not significantly different. At the end of follow-up,
74.42% of the patients were in NYHA functional class I or
II. Twenty-seven percent of patients were in sinus rhythm,
63% were in atrial fibrillation, and 10% had a pacemaker.
Most patients (85.28%) were orally anticoagulated (warfa-
rin), including 87.28% who were in sinus rhythm.
Discussion
In the time interval of this study, 1799 mechanical prosthe-
ses and 561 biologic prostheses of different makes were
implanted. The indications for the use of bioprostheses were
identical to those recently reported by the American Heart
Association,12 with the adjunct of patients from underde-
veloped countries or from particularly underdeveloped areas
within the country. This study summarizes our 15-year
experience with the use of the Hancock II porcine biopros-
thesis.
Clinical durability of first-generation porcine bioprosthe-
ses was limited by calcification and primary cusp
tears.2,13-16 Improvements were obtained by eliminating the
right muscle shelf, preserving the natural collagen crimping
with glutaraldehyde fixation at low pressure, designing a
new stent (Delrin), and adding an anticalcification treatment
with sodium dodecyl sulfate (T6) to enhance both hemody-
namic performance and long-term durability. In our institute
the clinical use of the Hancock II model started in 1983, and
in 1994, Bortolotti and colleagues5 reported excellent inter-
mediate-term results with no evidence of calcification at a
mean follow-up of 4.5  2.6 years. In 1995, Bortolotti and
colleagues17 documented an improved long-term survival
and durability up to 8 years with the Hancock II biopros-
thesis compared with that of the Hancock Standard biopros-
thesis. This conclusion was recently supported by Ikonomi-
dis and coworkers18 and is also confirmed from the 15-year
freedom from SVD we are reporting in this article, which
was higher both in the aortic and the mitral position than
that previously reported for patients receiving the Hancock
Standard bioprosthesis (P  .001).17 Nevertheless, these
observations are seriously confounded by differences in
operative age, which was 48  12 years in the Hancock
Standard series reported by Bortolotti and colleagues17
Figure 3. Kaplan-Meier 15-year freedom from SVD by position. The 95% confidence band (C.L.) is shown.
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compared with 63  9 years in the present Hancock II
series.
Clinical Results
Compared with the series by David and associates19 and
Legarra and coworkers20, the overall 15-year Kaplan-Meier
survival of our experience was lower. The article by Legarra
and coworkers on long-term results with the Hancock II
valve appears unreliable because they claim to have started
implantation in 1978 despite the fact that clinical use of the
Hancock II bioprosthesis dates only to 1983. The excellent
results of the article by David and associates19 are probably
difficult to reproduce. However, our survival with the Han-
cock II valve is within the international standard and similar
to recent results21 obtained in Sweden with the Biocor
porcine valve (St Jude Medical, Inc, St Paul, Minn), a
new-generation prosthesis with zero pressure fixation, com-
posite leaflets, and a low-profile flexible acetal copolymer
(Celcon) stent, which started to be used in 1983.
The perioperative mortality of our single-valve series
compared with that in the series by David and associates,19
which does not include double-valve replacements, was
higher: 8.8% (16/180) versus 5.8% (57/980, P  .12). The
difference was probably related to NYHA class II and IV
prevalence (87% vs 79%) and to the higher reoperation
prevalence of our series (34% of patients vs 25% of patients
in the series by David and associates). In fact, almost half of
our perioperative deaths occurred in patients who had un-
dergone previous valve operations. Our patients undergoing
aortic operations were older (P  .07) and our patients
undergoing mitral valve replacement were younger (P 
.001) than those in the study by David and associates.19
These differences confounded late survival and late com-
plication comparisons between the 2 series. Small differ-
ences in operative ages were responsible for large differ-
ences in survival at 15 years, when natural death obscured
disease-specific mortality. Compared with the results of the
series by David and associates, we reported a higher inci-
dence of thromboembolic events. Our protocol did not in-
clude the use of aspirin therapy, anticoagulation control was
in the physicians’ hands, and anticoagulation clinic support
was rare. Hemorrhagic events were related to anticoagula-
tion use in 87% of patients in sinus rhythm, losing one of the
theoretical advantages of bioprosthetic devices. Moreover,
despite high reoperation rates, young patients had very
satisfactory long-term survival, confirming that biopros-
thetic reoperations did not seriously affect survival, as pre-
viously reported.19
Noteworthy is our finding of 3 thrombosed valves, which
was previously reported in a Hancock Standard series.22
Unfortunately, just a single patient underwent reoperation.
The operative notes recorded an atrial thrombosis with
extension to the valve, which was surgically cleaned and
preserved without further complications. The pathogenesis
remained unclear in the other 2 patients.
Endocarditis was rare and mostly in the mitral position,
as documented in previous reports.19-21 When occurring, it
was aggressive and lethal.
Paravalvular leak was also rare and more frequent in
patients undergoing double-valve replacement.
Figure 4. Actual 15-year freedom from SVD according to operative age.
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Structural Valve Deterioration
We observed 22 cases of SVD (72% 15-year actuarial
freedom and 88% actual freedom). Seventeen patients un-
derwent reoperation, and 3 died.
Actuarial Kaplan-Meier and actual freedom from SVD
were significantly lower in the mitral than in the aortic
position, as previously reported.19 In the aortic position,
overall 15-year actual results, as well as age-stratified re-
sults, were identical to the results observed by Banbury and
associates23 with the use of the Carpentier-Edwards bovine
pericardial valve (Edwards Lifesciences, Irvine, Calif). In
the mitral position the overall 10-year actuarial freedom of
SVD was 86%  4.7%, which was similar to the results of
the Carpentier-Edwards pericardial valve research reported
by Jamieson and coworkers24 and superior to the results
observed with the Carpentier-Edwards supra-annular por-
cine valve, despite the younger overall age of patients
undergoing mitral valve replacement in our series (61  9
vs 64  12 years).
Younger patients were significantly more affected by
SVD than older patients. By means of age stratification,
only the mitral position was a significant incremental risk
factor limited to the younger age group, possibly because of
the small number of our younger patients undergoing aortic
valve replacement (26/66). Therefore we consider younger
age and mitral position predictive of SVD, as previously
stated by David and associates.19 In patients undergoing
isolated aortic procedures, 100% 15-year actual freedom
from SVD was observed if age at the time of the operation
was 65 years or greater. This result, which is identical to
that reported in the article by Jamieson and colleagues,25
adds to confidence in the use of aortic Hancock II prostheses
by adding 4 more patients, who were followed by us for 15
years, to the 5 reported in their article.
The higher failure propensity of the Hancock II mitral
valve might be ascribed to hemodynamic factors ( pres-
sure and shear stress) unique to this position.19 Increased
commissural stress caused by low-profile design has been
indicated as a possible cause of the high failure rate of the
supra-annular Carpentier-Edwards porcine valve.24 How-
ever, a lower reoperation rate caused by mitral SVD com-
pared with aortic SVD has been reported at 15-year fol-
low-up by Myken and colleagues21 with the use of the
Biocor porcine prosthesis and by Bottio and coworkers26 at
9 years’ follow-up.
Unlike Butany and associates,27 we did not observe SVD
cases with pannus overgrowth. Butany and associates
pointed out that the high prevalence of pannus (60% of
explanted mitral valves) might be due to the preservation of
TABLE 3. Causes of reoperation
Failure Aortic Mitral Mitral-aortic
Endocarditis 2
SVD 1 12 4
Paravalvular leak* 1 2
Prophylactic replacement† 2
Left atrium and prosthetic toilette‡ 1
Unknown§ 2
Total 1 20 6
*Dehiscence: prosthesis annulus detachment.
†Reoperation because of other valve-related complications.
‡Prosthetic-sparing procedure.
§Patients reoperated elsewhere.
Figure 5. Kaplan-Meier 15-year freedom from reoperation. The 95% confidence band (C.L.,) is shown.
Rizzoli et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 73
A
CD
the mitral subvalvular apparatus, a policy that we seldom
used during the time span of the study. Fibrous pannus
formation on the porcine cusps of the ventricular side has
been observed in tricuspid replacement28,29 and related to
excessive prosthetic dimension.30 We implanted mitral bio-
prostheses larger on average than those reported by David
and associates,19 thus excluding this possible mechanism.
In conclusion, our perioperative mortality was probably
related to previous valve operations. The incidence of all
valve-related complications was low in both the aortic and
the mitral position. Hancock II bioprostheses had excellent
15-year durability when compared with previous results
with Hancock Standard bioprostheses, possibly because of
anticalcification treatment mitigating mineralization, al-
though this remains to be proved. This is an important
finding because of the exponential increase of patients with
degenerative aortic valve stenosis in aging populations.
Although the oldest patients will experience the largest
advantage, it is noteworthy that younger aortic patients
might enjoy anticoagulation freedom at low SVD risk with
this prosthesis.
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